Gene therapy
Human evidence and active trials are visible in this field
3 human-evidence records · 12 active trials · 18 visible funding records · 5,632 universities
Longevity Patent Family
METHODS OF IMMORTALIZING PRIMARY RESTING T CELLS BY CRISPR/DCAS9-BASED EPIGENETIC MODIFIERS AND TRANSCRIPTIONAL ACTIVATORS
Source-linked patent metadata for METHODS OF IMMORTALIZING PRIMARY RESTING T CELLS BY CRISPR/DCAS9-BASED EPIGENETIC MODIFIERS AND TRANSCRIPTIONAL ACTIVATORS, including priority, record stage and longevity-topic connections.
Patent-family snapshot
Application publication visible
Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.
- Representative publication
- US20260092294A1
- Earliest priority
- September 30, 2024
- Latest publication
- April 2, 2026
- Family publications
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Organizations named in this family
Topics connected by metadata
Gene therapy88% metadata match
What this family cites
- Earlier patent references
- 0
- Scientific and other non-patent references
- 0
- Priority dates represented
- 1
References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →